Japan Lifeline Co., Ltd. has entered into an exclusive distribution agreement with Haemonetics Japan GK for VASCADE MVPTM, a vascular closure device for femoral veins used after ablation surgery for atrial fibrillation, on June 28, 2023 in Japan. The product received regulatory approval in April of this year and is scheduled to be launched in the third quarter of the fiscal year ending March 31, 2024. In atrial fibrillation ablation surgery, the femoral vein is punctured to secure an access route to carry the catheter to the heart, and the puncture site is closed after the procedure is completed.

VASCADE MVPTM uses a catheter to deliver a collagen plug into the tissue tract, where the absorbable collagen absorbs tissue fluid and blood, expands, and coagulates to stop bleeding. The Company will strive to promote the use of VASCADE MVPTM as this product will enable a reduction in hemostasis time, which will benefit both patients and medical professionals.